Milestone Scientific implements its CompuFlo® Epidural System at Pain Doctors Medical LLC to enhance safety and efficiency in pain management.
Quiver AI Summary
Milestone Scientific Inc. has announced the commercial rollout of its CompuFlo® Epidural System at Pain Doctors Medical LLC, enhancing patient safety and efficiency in pain management procedures. The system, developed using proprietary Dynamic Pressure Sensing Technology®, allows for real-time verification of epidural needle placement, increasing procedural accuracy and reducing complications. Dr. Ilana Etelzon, who evaluated the technology, praised its ability to provide peace of mind to both patients and physicians. The launch follows recent Medicare reimbursement assignments, which are expected to enhance accessibility to this innovative technology in interventional pain management. Milestone's leadership sees this expansion as pivotal for growth within the sector, aiming to broaden adoption of the CompuFlo® system among leading pain management providers.
Potential Positives
- Milestone Scientific announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical LLC, enhancing its presence in interventional pain management.
- The successful evaluation by Dr. Ilana Etelzon, a board-certified expert, supports the system's clinical effectiveness and safety in real-world applications.
- The recent Medicare price assignment for the CompuFlo® Epidural System increases accessibility for the technology across pain management facilities.
- The Chairman and Interim CEO expressed optimism for accelerated growth within the sector due to strengthening reimbursement coverage and the system's recognized clinical benefits.
Potential Negatives
- Potential over-reliance on favorable forward-looking statements that may not materialize, indicating uncertainty about future growth and market conditions.
- Forward-looking statements are accompanied by significant risks and uncertainties, which could deter investors concerned about the company's financial health.
FAQ
What is the CompuFlo® Epidural System?
The CompuFlo® Epidural System is a computerized drug delivery instrument that uses Dynamic Pressure Sensing Technology® for precise epidural injections.
Who is Dr. Ilana Etelzon?
Dr. Ilana Etelzon is a board-certified expert in Interventional Pain Management and has integrated the CompuFlo® Epidural System into her practice.
How does the CompuFlo® technology improve patient safety?
The technology provides real-time verification of epidural needle placement, enhancing procedural accuracy and reducing the risk of complications.
What impact does Medicare price assignment have on the CompuFlo® system?
The Medicare price assignment is expected to improve accessibility to the CompuFlo® system across interventional pain management centers.
What advancements does Milestone Scientific aim for in pain management?
Milestone Scientific aims to broaden the adoption of the CompuFlo® technology to enhance patient care and procedural efficiency within pain management.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLSS Insider Trading Activity
$MLSS insiders have traded $MLSS stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $MLSS stock by insiders over the last 6 months:
- LEONARD OSSER has made 0 purchases and 2 sales selling 249,897 shares for an estimated $235,242.
- MICHAEL MCGEEHAN has made 0 purchases and 4 sales selling 23,009 shares for an estimated $18,541.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLSS Hedge Fund Activity
We have seen 13 institutional investors add shares of $MLSS stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- Y-INTERCEPT (HONG KONG) LTD added 52,368 shares (+inf%) to their portfolio in Q3 2024, for an estimated $47,681
- KESTRA ADVISORY SERVICES, LLC added 41,100 shares (+inf%) to their portfolio in Q3 2024, for an estimated $37,421
- VANGUARD GROUP INC added 34,556 shares (+1.6%) to their portfolio in Q3 2024, for an estimated $31,463
- GEODE CAPITAL MANAGEMENT, LLC added 31,572 shares (+6.4%) to their portfolio in Q3 2024, for an estimated $28,746
- CITADEL ADVISORS LLC removed 31,169 shares (-57.4%) from their portfolio in Q3 2024, for an estimated $28,379
- RADNOR CAPITAL MANAGEMENT, LLC added 31,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $29,760
- WELLS FARGO & COMPANY/MN removed 30,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $27,315
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical LLC, a specialized interventional pain management center. This rollout follows a successful evaluation led by Dr. Ilana Etelzon, MD, a board-certified expert in Interventional Pain Management and Physical Medicine & Rehabilitation Medicine, who has integrated the technology into her practice to enhance patient safety and procedural efficiency.
The CompuFlo® Epidural System uses Milestone Scientific’s proprietary Dynamic Pressure Sensing Technology® to provide real-time verification of epidural needle placement. This precision-driven approach improves safety and reduces the risk of complications, allowing for greater confidence in pain management procedures.
Dr. Etelzon commented, “The CompuFlo® Epidural System represents a significant advancement in epidural administration. The ability to confirm needle placement with real-time feedback not only enhances procedural accuracy but also provides peace of mind for both physicians and patients. Integrating this technology into my practice at Pain Doctors Medical LLC allows us to deliver safer and more effective pain management solutions.”
This launch follows the recent Medicare price assignment for the CompuFlo® Epidural System, which is helping drive broader accessibility across interventional pain management and rehabilitation centers. With a strong track record of clinical validation, the system is increasingly being recognized as an essential tool for improving patient care.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, added, “Expanding our reach within interventional pain management centers like Pain Doctors Medical LLC is a crucial step in broadening the reach of our CompuFlo® technology. Dr. Etelzon’s positive experience with the system reaffirms its clinical benefits, and we are committed to furthering its adoption across leading pain management providers. As reimbursement coverage continues to strengthen, we anticipate accelerating growth within this sector.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology
®
instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the
MLSS brand video
or visit
milestonescientific.com
.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023 . The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email:
[email protected]
Tel: 212-671-1020